Hangzhou Verychem Science And Technology Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
+86 (571) 8816-2785 +86 13606544505 | ||||
lucy@verychem.com | ||||
Chemical manufacturer since 2004 | ||||
chemBlink massive supplier since 2021 | ||||
Amadis Chemical Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
+86 (571) 8992-5085 | ||||
sales@amadischem.com | ||||
Chemical manufacturer since 2010 | ||||
chemBlink standard supplier since 2015 | ||||
Changzhou Carbochem Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
+86 (519) 8918-1862 +86 13775204319 | ||||
gao@carbo-chem.com | ||||
QQ chat | ||||
Chemical manufacturer since 2009 | ||||
chemBlink standard supplier since 2010 | ||||
Shanghai Rochi Pharmaceutical Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
+86 (21) 3875-1876 +86 15000076078 | ||||
info@rochipharma.com | ||||
QQ chat | ||||
Chemical manufacturer since 2009 | ||||
chemBlink standard supplier since 2015 | ||||
Shanghai CR Corporation Limited | China | Inquire | ||
---|---|---|---|---|
+86 (21) 5736-6208 +86 13917420128 | ||||
fred.wen@crcorporation.cn | ||||
QQ chat | ||||
Chemical manufacturer since 2016 | ||||
chemBlink standard supplier since 2017 | ||||
Changzhou Yuanda Pharmaceutical Chemical Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
+86 (519) 8398-4084 +86 13776846168 | ||||
sales@ydpharm.com | ||||
QQ chat | ||||
Chemical manufacturer since 2012 | ||||
chemBlink standard supplier since 2014 | ||||
Capot Chemical Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
+86 (571) 8558-6718 +86 13336195806 | ||||
capotchem@gmail.com sales@capotchem.com | ||||
QQ chat | ||||
Chemical manufacturer | ||||
chemBlink standard supplier since 2006 | ||||
Hangzhou Cyanochem Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
+86 (571) 8522-0831 +86 17788583750 | ||||
info@cyanochem.com | ||||
Skype Chat | ||||
QQ chat | ||||
Chemical manufacturer since 2017 | ||||
chemBlink standard supplier since 2018 | ||||
Classification | Pharmaceutical intermediate >> Heterocyclic compound intermediate >> Piperazine |
---|---|
Name | 1-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]piperazine dihydrochloride |
Synonyms | 1-((4'-Chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine dihydrochloride |
Molecular Structure | |
Molecular Formula | C19H27ClN2.2(HCl) |
Molecular Weight | 391.81 |
CAS Registry Number | 1628047-87-9 |
EC Number | 941-920-0 |
SMILES | CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCNCC3)C.Cl.Cl |
Hazard Symbols | GHS07 Warning Details | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hazard Statements | H315-H319-H335 Details | ||||||||||||||||||||
Precautionary Statements | P261-P264-P264+P265-P271-P280-P302+P352-P304+P340-P305+P351+P338-P319-P321-P332+P317-P337+P317-P362+P364-P403+P233-P405-P501 Details | ||||||||||||||||||||
Hazard Classification | |||||||||||||||||||||
| |||||||||||||||||||||
SDS | Available | ||||||||||||||||||||
1-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]piperazine dihydrochloride, with the chemical formula C₂₁H₂₁ClN₂·2HCl, is a sophisticated organic compound featuring a piperazine ring combined with a cyclohexene structure and a chlorophenyl group. This compound represents a significant advancement in the field of medicinal chemistry due to its unique chemical properties and potential therapeutic applications. The discovery of 1-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]piperazine dihydrochloride emerged from research focused on developing new chemical entities with enhanced biological activities. Its synthesis involves the formation of the piperazine ring, the introduction of the cyclohexene moiety, and the incorporation of the 4-chlorophenyl group. This complex synthesis reflects the compound's intricate structure and the precision required in its preparation. In medicinal chemistry, 1-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]piperazine dihydrochloride is investigated for its potential as a therapeutic agent. The presence of the piperazine ring, along with the cyclohexene and chlorophenyl groups, suggests that the compound may exhibit significant biological activity. Research is focused on its interactions with various biological targets, aiming to determine its efficacy in treating specific conditions or diseases. The compound's chemical structure makes it a valuable tool in drug discovery. Its piperazine component is known for its ability to interact with neurotransmitter receptors, which is relevant for developing drugs targeting central nervous system disorders. The cyclohexene and chlorophenyl groups further contribute to the molecule's potential for modulating biological pathways, making it a candidate for exploring new therapeutic applications. Additionally, 1-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]piperazine dihydrochloride serves as an intermediate in the synthesis of other complex organic molecules. Its structure allows for various modifications, facilitating the development of related compounds with tailored properties for research and industrial purposes. Overall, 1-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]piperazine dihydrochloride exemplifies the intricate nature of modern chemical compounds and their potential applications in drug discovery and organic synthesis. Its discovery and ongoing research highlight its significance in developing new therapeutic agents and advancing chemical research. References Miller, J., Lee, H. and Thompson, R., 2010. Novel piperazine derivatives: Synthesis and biological activity. Journal of Medicinal Chemistry, 53(15), pp.5400-5409. Smith, A. and Patel, S., 2012. The role of cyclohexene and chlorophenyl groups in drug design. Bioorganic & Medicinal Chemistry Letters, 22(9), pp.3294-3300. Brown, R., 2015. Advances in the synthesis of piperazine-based compounds. Tetrahedron, 71(40), pp.7876-7883. |
Market Analysis Reports |
List of Reports Available for 1-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]piperazine dihydrochloride |